RAB11A: A Potential Drug Target and Biomarker (G8766)

Target Name: RAB11A

NCBI ID: G8766

RAB11A

RAB11A: A Potential Drug Target and Biomarker

RAB11A is a gene that encodes a protein involved in the regulation of cell adhesion and signaling pathways. The protein encoded by RAB11A has been shown to play a role in several cellular processes, including the development and maintenance of neural tissues, the regulation of inflammation and fibrosis, and the control of cell cycle progression.

The RAB11A gene has four splice variants, RAB11A-1, RAB11A-2, RAB11A-3, and RAB11A-4. RAB11A-1 and RAB11A-2 are predominantly expressed in the brain, while RAB11A-3 and RAB11A-4 are expressed in various tissues and organs, including the heart, pancreas, and skin.

The function of RAB11A has been studied extensively, and several studies have suggested that it may be a potential drug target. One of the main reasons for this is the evidence that RAB11A has been shown to regulate several cellular processes, including cell adhesion, migration, and invasion.

Additionally, RAB11A has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, RAB11A has been shown to be overexpressed in several types of cancer, including breast, ovarian, and colorectal cancer. This suggests that targeting RAB11A may be a promising strategy for the development of new treatments for these diseases.

Another potential mechanism by which RAB11A may be targeted as a drug is its role in regulating cell cycle progression. Several studies have shown that RAB11A plays a role in the regulation of G1-S transition, a critical step in the cell cycle that involves the preparation of the cell for cell division.

Furthermore, RAB11A has been shown to interact with several other genes, including TP53, a tumor suppressor gene that plays a critical role in the regulation of cell cycle progression and apoptosis. This suggests that targeting RAB11A with drugs that can inhibit its function may be a promising strategy for the treatment of cancer.

In addition to its potential role as a drug target, RAB11A has also been shown to be a potential biomarker. Several studies have shown that RAB11A can be used as a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

For example, RAB11A has been shown to be overexpressed in several types of cancer, including breast, ovarian, and colorectal cancer. This suggests that targeting RAB11A with drugs that can inhibit its function may be a promising strategy for the development of new treatments for these diseases.

In addition, RAB11A has also been shown to be overexpressed in several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that targeting RAB11A with drugs that can inhibit its function may be a promising strategy for the treatment of these diseases.

Finally, RAB11A has also been shown to be overexpressed in several autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. This suggests that targeting RAB11A with drugs that can inhibit its function may be a promising strategy for the treatment of these diseases.

In conclusion, RAB11A is a gene that has been shown to play a role in several cellular processes, including the development and maintenance of neural tissues, the regulation of inflammation and fibrosis, and the control of cell cycle progression. The protein encoded by RAB11A has also been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

These findings suggest that targeting RAB11A with drugs that can inhibit its function may be a promising strategy for the development of new treatments for these diseases. Further research is needed to fully understand the role of RAB11A

Protein Name: RAB11A, Member RAS Oncogene Family

Functions: The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different set of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion. The small Rab GTPase RAB11A regulates endocytic recycling. Acts as a major regulator of membrane delivery during cytokinesis. Together with MYO5B and RAB8A participates in epithelial cell polarization. Together with RAB3IP, RAB8A, the exocyst complex, PARD3, PRKCI, ANXA2, CDC42 and DNMBP promotes transcytosis of PODXL to the apical membrane initiation sites (AMIS), apical surface formation and lumenogenesis. Together with MYO5B participates in CFTR trafficking to the plasma membrane and TF (Transferrin) recycling in nonpolarized cells. Required in a complex with MYO5B and RAB11FIP2 for the transport of NPC1L1 to the plasma membrane. Participates in the sorting and basolateral transport of CDH1 from the Golgi apparatus to the plasma membrane. Regulates the recycling of FCGRT (receptor of Fc region of monomeric Ig G) to basolateral membranes. May also play a role in melanosome transport and release from melanocytes

The "RAB11A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAB11A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets